Tarsus Pharmaceuticals (TARS) Revenue (2021 - 2026)

Tarsus Pharmaceuticals' Revenue history runs 6 years deep, the most recent figure standing at $162.1 million for Q1 2026.

• In Q1 2026, Revenue rose 106.87% year-over-year to $162.1 million; the TTM figure through Mar 2026 stood at $535.1 million (up 128.99% YoY), while the FY2025 annual figure was $451.4 million, up 146.71% from the prior year.
• Revenue was $162.1 million for Q1 2026 at Tarsus Pharmaceuticals, up from $151.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $162.1 million in Q1 2026 to a low of $539000.0 in Q1 2022.
• Historically, Revenue has averaged $56.0 million across 5 years, with a median of $40.8 million in 2024.
• Biggest YoY gain for Revenue was 2858.58% in 2022; the steepest drop was 98.39% in 2022.
• A 5-year view of Revenue shows it stood at $10.0 million in 2022, then jumped by 30.76% to $13.1 million in 2023, then jumped by 407.86% to $66.4 million in 2024, then surged by 128.39% to $151.7 million in 2025, then grew by 6.85% to $162.1 million in 2026.
• The last three Revenue figures came in at $162.1 million (Q1 2026), $151.7 million (Q4 2025), and $118.7 million (Q3 2025), per Business Quant data.